Biotechnology

Pharma veteran Shyamakant Giri takes the helm at Apothecon Group, signaling an aggressive push into global regulated markets backed by Everstone Capital.

Glucotrack seeks FDA trial approval for its revolutionary 3-year implantable glucose monitor, racing against financial clocks to change diabetes care.

As its CFO presents at a top NYC conference, Healios K.K. advances novel stem cell treatments for ARDS, stroke, and cancer into critical global trials.

Edesa Biotech pushes its pipeline forward with a new vitiligo trial and promising ARDS data, but rising R&D costs highlight the high stakes of innovation.

The biotech firm is set to launch its first commercial products, using an innovative strategy to tackle long-neglected markets in women's healthcare.

A key workshop aims to bridge the gap between FDA policy and patient needs, seeking to streamline therapy development for millions with rare diseases.

The Nexus Forum launches to connect China's booming biotech scene with global pharma, capitalizing on a major shift in worldwide drug discovery and deal-making.

NFL legend Brett Favre reports gains from an experimental Parkinson's drug, but what does the science say about this potential breakthrough treatment?

Senti Biosciences advances its AML cell therapy to a registrational trial after FDA meeting and a key discovery that quadruples patient response rates.

Rubicon Point Partners and Canyon Partners Real Estate acquired a Santa Clara R&D campus, signaling a major bet on Silicon Valley's real estate backed by accelerating demand for specialized flex space.

The biopharma posts record Q1 revenue and profit, driven by its flagship DefenCath and a key acquisition, while a promising pipeline signals future growth.

OrganOx names Terumo's Naoya Iwata as new CEO, signaling a major push to expand its life-saving organ transplant technology across the globe.

A federal jury exonerated hedge fund Armistice Capital of all fraud claims related to Vaxart's COVID-era stock surge, a major trial loss for investors.

With a new CFO known for big-ticket financing and IPO readiness, clinical-stage OnCusp Therapeutics is gearing up for its next major growth spurt.

Early human trial data for a new drug, UDP-003, suggests it can safely remove toxic cholesterol, a key step toward reversing arterial plaque buildup.

Fresh off its IPO, Agomab Therapeutics is presenting key data for its new IPF drug, AGMB-447, while courting investors on a multi-conference tour.

Atamyo's new gene therapy shows remarkable early results, potentially halting a severe, progressive muscular dystrophy that affects children.

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

METiS TechBio's stock surged over 170% on its debut, as investors bet big on its AI-powered platform to build the future of precision drug delivery.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.